Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jack Waxman

Rheumatology Santa Rosa, CA Medical Doctor

NPI 1104824994 CMS profile 231059

4015 Quartz Dr, Santa Rosa, CA 95405

Open in the dashboard

General payments

$75,335

930 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jack Waxman of Santa Rosa, CA is reported in the CMS Open Payments database as having received $75,335 across 930 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,058 25
2024 General $998 19
2023 General $648 18
2022 General $605 28
2021 General $6,374 188
2020 General $14,878 297
2019 General $50,774 355

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Waxman
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Jack Waxman were reported at $1,058. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Jack Waxman Rheumatology median Middle half National median
2019 $50,774 $744 $153–$2,687 $163
2020 $14,878 $462 $98–$2,027 $114
2021 $6,374 $531 $101–$2,153 $132
2022 $605 $627 $125–$2,303 $149
2023 $648 $741 $145–$2,524 $160
2024 $998 $830 $166–$2,660 $164
2025 $1,058 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $31,440 288 payments
  2. Novartis Pharmaceuticals Corporation $24,099 83 payments
  3. Pfizer Inc. $5,159 69 payments
  4. AbbVie, Inc. $3,268 107 payments
  5. Horizon Therapeutics plc $3,144 21 payments
  6. Radius Health, Inc. $1,356 72 payments
  7. GlaxoSmithKline, LLC. $832 40 payments
  8. Janssen Scientific Affairs, LLC $829 13 payments
  9. Janssen Biotech, Inc. $662 43 payments
  10. E.R. Squibb & Sons, L.L.C. $542 21 payments
  11. Other $4,004 173 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $42,118 20 payments
  2. Food and Beverage $20,771 846 payments
  3. Travel and Lodging $7,257 29 payments
  4. Honoraria $4,680 2 payments
  5. Education $384 32 payments
  6. Consulting Fee $125 1 payment
Products named General payments · program years 2019–2025
  1. Prolia $25,905 175 payments
  2. COSENTYX Immunology $23,138 80 payments
  3. EVENITY $6,406 146 payments
  4. XELJANZ $4,498 45 payments
  5. KRYSTEXXA $2,923 4 payments
  6. RINVOQ $1,112 24 payments
  7. COSENTYX Dermatology $961 3 payments
  8. HUMIRA $950 44 payments
  9. Tymlos $950 54 payments
  10. BENLYSTA $832 40 payments
  11. Other $10,737 516 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$127,554

Medicare's payments for the services billed

Medicare patients

84

Average age 75

Services billed

1,710

42 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 63%
Arthritis 55%
Alzheimer's or dementia 48%
Chronic kidney disease 46%
Diabetes 44%
Heart failure 40%
Atrial fibrillation 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
  • UCB, Inc. $186
$186 — —
TREMFYA
  • Janssen Scientific Affairs, LLC $169
$169 — —
EVENITY
  • Amgen Inc. $144
$144 — —
RINVOQ
  • AbbVie, Inc. $115
$115 — —
TAVNEOS
  • Amgen Inc. $101
$101 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

930 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record